Natixis Advisors LLC Sells 1,056,986 Shares of DexCom, Inc. (NASDAQ:DXCM)

Natixis Advisors LLC reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 96.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,408 shares of the medical device company’s stock after selling 1,056,986 shares during the period. Natixis Advisors LLC’s holdings in DexCom were worth $2,373,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of DXCM. Capital Insight Partners LLC grew its stake in DexCom by 2.5% in the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after purchasing an additional 90 shares in the last quarter. HM Payson & Co. increased its stake in DexCom by 6.0% during the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after acquiring an additional 100 shares during the period. Clear Creek Financial Management LLC grew its holdings in shares of DexCom by 4.2% during the 2nd quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock worth $336,000 after purchasing an additional 120 shares in the last quarter. SeaCrest Wealth Management LLC increased its holdings in DexCom by 3.6% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock valued at $501,000 after buying an additional 152 shares during the period. Finally, Securian Asset Management Inc. increased its stake in DexCom by 0.7% in the second quarter. Securian Asset Management Inc. now owns 22,866 shares of the medical device company’s stock valued at $2,593,000 after acquiring an additional 161 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Price Performance

NASDAQ DXCM opened at $72.83 on Monday. The stock has a market capitalization of $28.45 billion, a price-to-earnings ratio of 43.61, a PEG ratio of 2.28 and a beta of 1.17. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The business’s fifty day moving average price is $70.61 and its 200-day moving average price is $89.55.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,431 shares of company stock worth $399,319 over the last three months. 0.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on DXCM shares. Robert W. Baird upped their price objective on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, August 5th. JPMorgan Chase & Co. increased their target price on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Oppenheimer lowered their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Piper Sandler reiterated an “overweight” rating and set a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. Finally, Royal Bank of Canada decreased their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.